230 related articles for article (PubMed ID: 37487027)
21. Synthesis and Evaluation of
Bendre S; Zhang Z; Colpo N; Zeisler J; Wong AAWL; Bénard F; Lin KS
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110717
[TBL] [Abstract][Full Text] [Related]
22. Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-α (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors.
Poplawski SE; Hallett RM; Dornan MH; Novakowski KE; Pan S; Belanger AP; Nguyen QD; Wu W; Felten AE; Liu Y; Ahn SH; Hergott VS; Jones B; Lai JH; McCann JAB; Bachovchin WW
J Nucl Med; 2024 Jan; 65(1):100-108. PubMed ID: 38050111
[TBL] [Abstract][Full Text] [Related]
23. Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time.
Moon ES; Ballal S; Yadav MP; Bal C; Van Rymenant Y; Stephan S; Bracke A; Van der Veken P; De Meester I; Roesch F
Am J Nucl Med Mol Imaging; 2021; 11(6):476-491. PubMed ID: 35003886
[TBL] [Abstract][Full Text] [Related]
24. Preparation and Bioevaluation of
Ruan Q; Feng J; Jiang Y; Zhang X; Duan X; Wang Q; Yin G; Xiao D; Zhang J
Mol Pharm; 2022 Jan; 19(1):160-171. PubMed ID: 34904839
[TBL] [Abstract][Full Text] [Related]
25. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and Preclinical Evaluation of Three Novel
Verena A; Zhang Z; Kuo HT; Merkens H; Zeisler J; Wilson R; Bendre S; Wong AAWL; Bénard F; Lin KS
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770755
[TBL] [Abstract][Full Text] [Related]
27. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [
Backhaus P; Gierse F; Burg MC; Büther F; Asmus I; Dorten P; Cufe J; Roll W; Neri D; Cazzamalli S; Millul J; Mock J; Galbiati A; Zana A; Schäfers KP; Hermann S; Weckesser M; Tio J; Wagner S; Breyholz HJ; Schäfers M
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1822-1832. PubMed ID: 34957527
[TBL] [Abstract][Full Text] [Related]
28. Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a
Varasteh Z; Mohanta S; Robu S; Braeuer M; Li Y; Omidvari N; Topping G; Sun T; Nekolla SG; Richter A; Weber C; Habenicht A; Haberkorn UA; Weber WA
J Nucl Med; 2019 Dec; 60(12):1743-1749. PubMed ID: 31405922
[TBL] [Abstract][Full Text] [Related]
29. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.
Wen X; Xu P; Shi M; Liu J; Zeng X; Zhang Y; Shi C; Li J; Guo Z; Zhang X; Khong PL; Chen X
Theranostics; 2022; 12(1):422-433. PubMed ID: 34987657
[No Abstract] [Full Text] [Related]
30. Clinical Evaluation of
Zhao L; Wen X; Xu W; Pang Y; Sun L; Wu X; Xu P; Zhang J; Guo Z; Lin Q; Chen X; Chen H
J Nucl Med; 2023 Aug; 64(8):1210-1217. PubMed ID: 37142301
[TBL] [Abstract][Full Text] [Related]
31. High Affinity and FAP-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake for FAP Inhibitors.
Wang Y; Yuan H; Liu N; Tang S; Feng Y; Liu Y; Cai P; Xia L; Zheng W; Chen Y; Zhou Z
J Med Chem; 2023 Jul; 66(13):8614-8627. PubMed ID: 37390480
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [
Zang J; Wen X; Lin R; Zeng X; Wang C; Shi M; Zeng X; Zhang J; Wu X; Zhang X; Miao W; Xu P; Guo Z; Zhang J; Chen X
Theranostics; 2022; 12(16):7180-7190. PubMed ID: 36276644
[TBL] [Abstract][Full Text] [Related]
33. Correlation of
Mona CE; Benz MR; Hikmat F; Grogan TR; Lueckerath K; Razmaria A; Riahi R; Slavik R; Girgis MD; Carlucci G; Kelly KA; French SW; Czernin J; Dawson DW; Calais J
J Nucl Med; 2022 Jul; 63(7):1021-1026. PubMed ID: 34740953
[TBL] [Abstract][Full Text] [Related]
34. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma:
Watabe T; Liu Y; Kaneda-Nakashima K; Shirakami Y; Lindner T; Ooe K; Toyoshima A; Nagata K; Shimosegawa E; Haberkorn U; Kratochwil C; Shinohara A; Giesel F; Hatazawa J
J Nucl Med; 2020 Apr; 61(4):563-569. PubMed ID: 31586001
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and preclinical evaluation of a novel PET/fluorescence dual-modality probe targeting fibroblast activation protein.
Zhang X; Huang J; Gong F; Cai Z; Liu Y; Tang G; Hu K
Bioorg Chem; 2024 May; 146():107275. PubMed ID: 38493637
[TBL] [Abstract][Full Text] [Related]
36. Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging.
Wang P; Wang S; Liu F; Ren Y; Guo Q; Zhang Q; Hou X; Yao Y; Zhu H; Yang Z
Mol Pharm; 2023 Feb; 20(2):1415-1425. PubMed ID: 36697367
[TBL] [Abstract][Full Text] [Related]
37. Rational Design and Pharmacomodulation of Protein-Binding Theranostic Radioligands for Targeting the Fibroblast Activation Protein.
Meng L; Fang J; Zhao L; Wang T; Yuan P; Zhao Z; Zhuang R; Lin Q; Chen H; Chen X; Zhang X; Guo Z
J Med Chem; 2022 Jun; 65(12):8245-8257. PubMed ID: 35658448
[TBL] [Abstract][Full Text] [Related]
38. Rational Design, Pharmacomodulation, and Synthesis of [
Lin JJ; Chuang CP; Lin JY; Huang FT; Huang CW
ACS Sens; 2021 Sep; 6(9):3424-3435. PubMed ID: 34415143
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and preclinical evaluation of a heterodimeric radioligand targeting fibroblast activation protein and integrin-α
Yan Q; Zhong J; Liu Y; Peng S; Feng P; Zhong Y; Hu K
Eur J Med Chem; 2023 May; 251():115279. PubMed ID: 36931125
[TBL] [Abstract][Full Text] [Related]
40. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention.
Loktev A; Lindner T; Burger EM; Altmann A; Giesel F; Kratochwil C; Debus J; Marmé F; Jäger D; Mier W; Haberkorn U
J Nucl Med; 2019 Oct; 60(10):1421-1429. PubMed ID: 30850501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
